CONNEQT Health

CONNEQT Health Financial Leverage

The Financial Leverage (Equity Multiplier) of CONNEQT Health (CQT.AX) as of Nov 16, 2026 is 14.72. In the previous year, Financial Leverage (Equity Multiplier) was 3.09 — a change of 375.61% (higher).

Financial Leverage

14.72

YoY

375.61%

Last updated:

Financial Leverage (Equity Multiplier) of CONNEQT Health is 2025 14.72 . Financial Leverage (Equity Multiplier) of CONNEQT Health was 2024 3.09 . It decreases by 375.61% higher compared to the previous year.

The CONNEQT Health Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.40 AUD
Jan 1, 2019
1.90 AUD
Jan 1, 2020
1.82 AUD
Jan 1, 2021
1.42 AUD
Jan 1, 2022
1.87 AUD
Jan 1, 2023
-19.42 AUD
Jan 1, 2024
3.09 AUD
Jan 1, 2025
14.72 AUD
The CONNEQT Health Financial Leverage history
YEARFinancial LeverageYoY
14.72+375.61%
3.09-115.93%
-19.42-1,137.45%
1.87+31.48%
1.42-21.57%
1.82-4.48%
1.90+36.21%
1.40-37.37%
2.23+52.02%
1.47+6.70%
1.37-2.68%
1.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CONNEQT Health Stock analysis

What does CONNEQT Health do? CardieX Ltd. generates revenue through its medical device business focused on cardiovascular management, targeting healthcare providers and pharmaceutical companies. The company offers clinical trial services across three geographic segments: Americas, Europe (including Middle East and Africa), and Asia Pacific (covering Asia and Australia/New Zealand). These services include study protocol assistance, operator training, data management, and technical support for global pharmaceutical trials. SphygmoCor technology is a key product used in clinical trials for therapeutic areas such as hypertension, renal disease, and heart failure. The firm's revenue streams are derived from its clinical trial services and SphygmoCor technology, which are sold to pharmaceutical companies conducting global trials. The Americas segment handles the global pharmaceutical trials business, while Europe and Asia Pacific segments support regional trial operations. SphygmoCor technology is specifically utilized in trials for cardiovascular and metabolic conditions, including COPD and diabetes. CardieX Ltd. serves pharmaceutical companies and healthcare institutions requiring cardiovascular management solutions and clinical trial support. Its products and services are tailored to therapeutic areas like hypertension, renal disease, heart failure, and inflammatory processes, with a focus on automated data transfer and expert over-read services for trial accuracy. CONNEQT Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CONNEQT Health stock

Financial Leverage (Equity Multiplier) of CONNEQT Health is 14.72 in 2025.

Financial Leverage (Equity Multiplier) of CONNEQT Health changed from 3.09 to 14.72, representing a 375.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) CONNEQT Health since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s CONNEQT Health with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — CONNEQT Health

All Key Metrics — CONNEQT Health